Catalyst Pharmaceuticals (CPRX) Accumulated Expenses (2010 - 2025)
Catalyst Pharmaceuticals' (CPRX) quarterly Accumulated Expenses came in at $136.0 million in Q4 2025, up 34848.59% YoY from N/an in Q4 2024, and up 13.63% on a QoQ basis from $119.6 million in Q3 2025.
Catalyst Pharmaceuticals (CPRX) Accumulated Expenses (2010 - 2025) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 16 years of Accumulated Expenses data on file, last reported at $136.0 million in Q4 2025.
- Quarterly Accumulated Expenses rose 34848.59% year-over-year to $136.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $136.0 million (up 34848.59% YoY) and the FY2025 annual result came in at $136.0 million, up 34848.59% from the prior year.
- Accumulated Expenses climbed to $136.0 million in Q4 2025, from $119.6 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $136.0 million in Q4 2025 to a low of $347000.0 in Q2 2025.
- A 5-year average of $41.7 million and a median of $33.2 million in 2021 frame the typical range for Accumulated Expenses.
- The widest YoY moves for Accumulated Expenses: up 34848.59% in 2025, down 99.59% in 2025.
- Tracing CPRX's Accumulated Expenses over 5 years: stood at $24.3 million in 2021, then surged by 120.68% to $53.6 million in 2022, then advanced by 14.28% to $61.3 million in 2023, then tumbled by 99.37% to $389000.0 in 2024, then jumped by 34848.59% to $136.0 million in 2025.
- The last three Accumulated Expenses figures came in at $136.0 million (Q4 2025), $119.6 million (Q3 2025), and $347000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 135.95 Mn |
| Sep 30, 2025 | 119.64 Mn |
| Jun 30, 2025 | 347,000.00 |
| Mar 31, 2025 | 6.61 Mn |
| Dec 31, 2024 | 389,000.00 |
| Sep 30, 2024 | 352,000.00 |
| Jun 30, 2024 | 85.20 Mn |
| Mar 31, 2024 | 69.31 Mn |
| Dec 31, 2023 | 61.27 Mn |
| Sep 30, 2023 | 53.21 Mn |
| Jun 30, 2023 | 48.08 Mn |
| Mar 31, 2023 | 53.32 Mn |
| Dec 31, 2022 | 53.61 Mn |
| Sep 30, 2022 | 42.15 Mn |
| Jun 30, 2022 | 20.17 Mn |
| Mar 31, 2022 | 17.80 Mn |
| Dec 31, 2021 | 24.30 Mn |
| Sep 30, 2021 | 17.86 Mn |
| Jun 30, 2021 | 13.21 Mn |
| Mar 31, 2021 | 11.88 Mn |